Clinical trial
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
NCT00400946 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00400946 |
|---|---|
| Title | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children |
| Official title | Treatment of Acute Lymphoblastic Leukemia in Children |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Leukemia |
| Intervention type | Drug, Radiation |
| Interventions | asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate and 6 more |
| Enrollment | 800 |
| Start date | Apr 1, 2005 |
| Primary completion | Aug 1, 2014 |
| Completion | Jun 1, 2019 |
| First posted | Nov 17, 2006 |
| Last update posted | Feb 13, 2026 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: